证券之星消息，10月15日南向资金减持5.5万股雍禾医疗（02279.HK）。近5个交易日中，获南向资金减 持的有5天，累计净减持13.9万股。近20个交易日中，获南向资金减持的有20天，累计净减持93.7万股。 截至目前，南向资金持有雍禾医疗（02279.HK）1740.9万股，占公司已发行普通股的3.31%。 雍禾医疗集团有限公司是一家控股公司，专门从事提供毛发相关医疗服务。该公司提供一站式毛发医疗 服务，涵盖植发医疗、医疗养固、常规养护及其他配套服务。该公司构建了以"雍禾医疗"为核心，由专 业植发品牌"雍禾植发"、医疗养固品牌"史云逊"、女性美学植发品牌"雍禾发之初"，及医学假发品 牌"哈发达"等组成的全产业链品牌矩阵。该公司建立独立的史云逊医学健发中心，为被毛发问题困扰的 患者进行医学检测、诊断与个性化护理治疗，以提供更专业的医疗毛发健康管理服务。该公司主要在中 国国内市场开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Yonghe Medical (02279.HK) by 12,000 shares on September 19, 2025, marking a total net reduction of 257,500 shares over the past five trading days and 1,214,000 shares over the past 20 trading days [1][2] - As of now, southbound funds hold 17,722,000 shares of Yonghe Medical, which accounts for 3.37% of the company's total issued ordinary shares [1][2] Group 2 - Yonghe Medical Group Limited is a holding company specializing in providing hair-related medical services, offering a one-stop solution that includes hair transplant medical services, medical hair care, routine maintenance, and other supporting services [2] - The company has established a brand matrix centered around "Yonghe Medical," which includes professional hair transplant brand "Yonghe Hair Transplant," medical hair care brand "Shiyunxun," female aesthetic hair transplant brand "Yonghe Hair Origin," and medical wig brand "Hafada" [2] - Yonghe Medical operates primarily in the domestic market of China, providing specialized medical hair health management services through its independent Shiyunxun Medical Hair Care Center [2]

Core Insights - Yonghe Medical (02279) reported a mid-term performance for the six months ending June 30, 2025, with revenue of RMB 862 million, a gross profit of RMB 550 million, representing a year-on-year increase of 3.9% [1] - The company achieved a net profit attributable to shareholders of RMB 27.913 million, marking a turnaround from a loss in the previous year, with earnings per share of RMB 0.06 [1] Company Overview - Yonghe Medical is a leading medical group in China specializing in hair medical services, offering a one-stop solution that includes hair transplantation, medical hair care, routine maintenance, and other related services [1] - The company has established a comprehensive brand matrix centered around "Yonghe Medical," which includes specialized brands such as "Yonghe Hair Transplant," "Shiyunxun" for medical hair care, "Yonghe Fazhichu" for women's aesthetic hair transplantation, and "Hafada" for medical wigs [1] Market Presence - As of June 30, 2025, the company operates 63 hair transplant medical institutions across 61 cities in China, making it the largest and most widely covered chain of hair medical services in the country [1] - The company served a total of 64,845 consumers during the six-month period ending June 30, 2025 [1]

Core Insights - The company reported a revenue of RMB 862 million for the six months ending June 30, 2025, with a gross profit of RMB 550 million, representing a year-on-year increase of 3.9% [1] - The company achieved a net profit attributable to shareholders of RMB 27.913 million, marking a turnaround from a loss in the previous year, with earnings per share of RMB 0.06 [1] Company Overview - The company is a leading medical group in China specializing in hair medical services, offering a comprehensive range of services including hair transplantation, medical hair care, routine maintenance, and other related services [1] - The company has established a full industry chain brand matrix centered around "Yonghe Medical," which includes specialized brands such as "Yonghe Hair Transplant," "Shiyunxun" for medical hair care, "Yonghe Fazhichu" for women's aesthetic hair transplantation, and "Hafada" for medical wigs [1] Market Presence - As of June 30, 2025, the company operates 63 hair transplant medical institutions across 61 cities in China, making it the largest and most widely covered chain of hair medical services in the country [1] - The company served a total of 64,845 consumers during the six-month period ending June 30, 2025 [1]

Core Insights - Yonghe Medical reported a revenue of 1.805 billion yuan for 2024, marking a 1.5% year-on-year increase, with EBITDA improving significantly to 141 million yuan [2][5] - The company has entered a self-adjustment phase since 2022, focusing on internal restructuring and breaking away from previous operational models to ensure long-term growth [2][4] Financial Performance - In 2024, Yonghe Medical paused its rapid expansion strategy, optimizing nine underperforming clinics, reducing the number of hair transplant institutions in second and third-tier cities from 51 to 42 [3] - The gross profit for 2024 increased by 8.7% to 1.084 billion yuan, with a gross margin of 60.1%, up 4% year-on-year [3][5] Market Position and Strategy - Yonghe Medical's hair transplant service revenue reached 1.331 billion yuan, accounting for 73.7% of total revenue, with an average patient expenditure of 22,300 yuan [5] - The company is building a comprehensive hair care system, expanding its service offerings beyond hair transplants to include preventive treatments and maintenance [6][8] Brand and Service Development - In 2024, Yonghe Medical introduced a brand strategy emphasizing the importance of skilled doctors and improved service quality, establishing a professional medical team of 1,401 members [9] - The company has implemented a transparent pricing model and innovative service delivery methods, enhancing patient trust and satisfaction [10] Future Outlook - The hair health market in China is projected to grow from 79.55 billion yuan in 2023 to 116.54 billion yuan by 2028, indicating significant growth potential for Yonghe Medical [6] - The company anticipates a continuous increase in demand for hair treatment and maintenance services, positioning itself to capitalize on the expanding market [11]

Group 1 - The core viewpoint of the news is that Yonghe Medical, known as the "first stock in hair transplantation," reported a revenue of RMB 1.805 billion for 2024, reflecting a year-on-year growth of 1.5% compared to 2023 [1] - The net loss for Yonghe Medical narrowed by 58.6% from RMB 550 million in 2023 to RMB 227 million in 2024 [1] - The gross profit for the company reached RMB 1.084 billion, representing an 8.7% increase year-on-year, with a gross margin of 60.1% compared to 56.1% in 2023 [1] Group 2 - Yonghe Medical provides a comprehensive range of hair medical services, including hair transplantation, medical care, routine maintenance, and other supporting services [3] - The total number of patients served by the company exceeded 120,000, with 59,655 patients undergoing hair transplantation, generating RMB 1.33 billion in revenue from hair transplantation services, accounting for 73.7% of total revenue [3] - The hair medical service market in China is experiencing rapid growth, with the market size increasing from RMB 58.29 billion in 2020 to RMB 79.55 billion in 2023, and is projected to reach RMB 116.54 billion by 2028 [3] Group 3 - In 2024, Yonghe Medical optimized its number of hair transplant clinics from 75 to 66 and reduced the number of independent stores from 13 to 8 [3] - The company explained that the optimization of the store network involved strategically closing and consolidating inefficient stores, reallocating resources to core locations, which significantly improved operational efficiency [3] - This strategic move not only enhanced the overall robustness of the business but also ensured effective resource utilization, further solidifying the company's competitive advantage in the market [3]